Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v13-EN Version v1-EN
Language English English
Date Updated 2022-02-02 2022-01-14
Drug Identification Number 02358808 02358808
Brand name PRADAXA PRADAXA
Common or Proper name PRADAXA 150MG PRADAXA 150MG
Company Name BOEHRINGER INGELHEIM (CANADA) LTD LTEE BOEHRINGER INGELHEIM (CANADA) LTD LTEE
Ingredients DABIGATRAN ETEXILATE DABIGATRAN ETEXILATE
Strength(s) 150MG 150MG
Dosage form(s) CAPSULE CAPSULE
Route of administration ORAL ORAL ORAL ORAL
Packaging size 6x10 6x10
ATC code B01AE B01AE
ATC description ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS
Reason for shortage Demand increase for the drug. Other (Please describe in comments)
Anticipated start date 2022-01-15 2022-01-15
Actual start date 2022-01-15
Estimated end date 2022-02-04 2022-01-21
Actual end date 2022-02-01
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Replenishment delivery delay to supply chain challenges (securing transportation).
Health Canada comments